From our origins as a spin out of Nottingham University to the global organization that we are today this year marks 35 years of Quotient Sciences helping clients accelerate drug development and advance new treatments to patients.
We are incredibly proud of our achievements and what our teams have done in this time to make a mark on improving health and wellbeing.
From our inception, innovation, customer service, and collaboration have been a focus of the business. We’ve kept sight of how to better serve our clients by finding time-saving, cost-effective, or novel ways to help our customers reach milestones more efficiently. This has included the creation of highly integrated approaches and operational models, like our Translational Pharmaceutics® platform.
Over the last three decades, we have worked on thousands of molecules—from cancer treatments to rare disease therapies—many of which are now positively impacting patient lives every day.
During recent presentations broadcasted from Nottingham to all colleagues globally, Dr. Ian Wilding, one of the company’s founders; Dr. Peter Scholes, former Chief Scientific Officer; and Dr. Andy Lewis, our current Chief Scientific Officer, discussed how the company started, where the company has been, its innovations, and the milestones ahead that will shape our future. Throughout the years, our team culture and collaboration have remained consistent and enabled us to deliver programs effectively for our clients.
To recognize the company’s track record of celebrating our history and impact, we’ve compiled a list of 35 interesting facts that best illustrate the story of Quotient Sciences’ 35 years.
Our story:
1. We work with emerging biotech firms and Fortune 500 pharma companies. Past and present clients include all of the leading large pharma and biotech companies in the world, representing a significant portion of the global pharmaceutical industry.
2. All new medicines undergo rigorous testing before they can be prescribed or sold, and the clinical trials run by Quotient Sciences are part of this process. We have a deep commitment to safety and quality.
3. We ask every customer for their feedback and we are proud to say that our average customer satisfaction score is 9 out of 10.
4. The company was founded in 1990 and was known as Pharmaceutical Profiles until 2009 when it changed to Quotient Bioresearch.
5. We first expanded to Edinburgh, adding data sciences to our portfolio of services. Co-Formulate, a UK-based CDMO, was acquired in 2015, to bring on board world leading expertise in pediatric product development.
6. The acquisition of Reading, UK-based Pharmaterials in 2017 added expertise in inhaled drug development and scale up capability to further expand our UK footprint.
7. 2017 was a milestone year, with a rebranding to Quotient Sciences and expansion to the U.S. Quotient Sciences acquired a CRO in Miami, FL (Seaview Research), and CDMO capacity in Philadelphia (QS Pharma).
8. Quotient Sciences expanded to Alnwick, UK in 2021, adding drug substance, bioanalysis, and a related portfolio of services.
9. Today, the Alnwick and Reading, UK facilities are part of Arcinova, which relaunched in 2025 to focus on early-stage drug development.
Our facilities & capabilities:
10. Collectively Quotient Sciences and Arcinova operate from 7 locations in the US and UK.
11. Our Philadelphia operations include two distinct facilities: Boothwyn and Garnet Valley. There are plans for a third facility to open in Garnet Valley in the future.
12. Eight FDA-approved therapies, including a pediatric cancer treatment, are currently produced in Philadelphia at our commercial product manufacturing site.
13. In 2020, we expanded our in-house compounding pharmacy in Miami, Fl, to support faster paths to FIH trials.
14. Our facility in Boothwyn, Pa. (Chelsea Parkway) was upgraded in 2025 for safer handling of HPAPI products, protecting our teams and adding capacity while ensuring we remain a drug product manufacturing partner of choice for our clients.
15. Our facility in Nottingham houses one of UK/EU’s largest and most experienced clinical pharmacology units and 6 co-located GMP rooms.
16. Between Miami and Nottingham, we have a total of 230 beds dedicated to early phase clinical trials in healthy volunteers and certain patient groups.
17. To date, our longest continuous clinical trial was in Miami, where a group of volunteers stayed for 60 consecutive days with us on-site as a single residency. In Nottingham, our longest continuous trial was 42 days.
18. In Miami, our longest clinical study duration was 1009 days (almost 3 years!)
Our innovations over the years:
19. Translational Pharmaceutics® is the company’s unique drug development platform. A comprehensive approach to formulation development, on-demand GMP manufacturing, and clinical testing that enables better outcomes for our clients.
20. Translational Pharmaceutics® was introduced nearly two decades ago and we’ve completed over 500 programs to date between our sites in the UK and US.
21. Our approach to project management is key in ensuring timely and budget-compliant delivery of drug development projects while maintaining high standards of quality and compliance, facilitating a smooth and efficient process from concept to final product.
22. The company was recognized recently with a Fierce CRO Award for innovation in drug development in 2024, and 2023 Pharma Innovation Award (Pharma Manufacturing).
23. We recently announced a partnership with UK-based CPI (Centre for Process Innovation) to improve mRNA therapy development, with the aim of bringing new treatments to patients faster by improving the pathways between manufacturing and clinical testing.
24. Our first Scientific Advisory Board was established earlier in 2025. The board will provide input on research and development priorities, technology investments, and scientific strategy.
25. Quotient Sciences is actively exploring AI to accelerate drug formulation and development processes.
26. In 2023, we presented over 25 posters along with having 5 speaking engagements at conferences and 4 papers in peer-reviewed journals. This momentum has continued. One highlight for 2025 was a co-authored paper with YourChoice Therapeutics published in Communications Medicine, a Nature Portfolio Journal, detailing the results of their Phase I study on a new, non-hormonal male birth control.
Our commitments to ESG, our colleagues & our future:
27. More than 1,100 talented colleagues work across the US, UK and parts of Europe to support a global mission: bringing molecules to cures, fast, for those in need.
28. Science, agility, and culture are the three pillars that define who we are and fuel our success.
29. ESG is central to how we operate. Our inaugural ESG report showed a 23% improvement in our EcoVadis sustainability score in 2023, and we proudly sustained that score in 2024—demonstrating our long-term dedication to sustainability.
30. 100% of our electricity usage in the UK was from renewable energy sources in 2024, and we purchased multiple renewable energy certificates (REC) in the US.
31. By signing the UN Global Compact, we’ve reinforced our commitment to ethical, transparent, and responsible business practices on a global scale.
32. Many of our new team members say they’ve found friendly, welcoming, and collaborative colleagues from day one, helping them feel part of something bigger.
33. We’re incredibly proud to have so many long-serving colleagues at Quotient Sciences, with 20+ years of service in some cases! They’ve witnessed first-hand the journey that’s shaped who we are today.
34. Quotient Sciences colleagues are always learning, evolving, and pushing boundaries to advance science and accelerate drug development.
35. Our colleagues are passionate about making a difference—knowing their work contributes to meaningful therapies that help patients around the world.
As the pharmaceutical landscape evolves, Quotient Sciences remains committed to its mission: bringing molecules to cures, fast. We continue to push boundaries with initiatives in artificial intelligence and mRNA therapy development, including a recently-announced joint venture with CPI.
“Every molecule we work on represents the potential to transform lives,” says CEO Thierry Van Nieuwenhove. “Our culture of collaboration, agility, and scientific excellence drives us to deliver on that promise.”